Douglass Winthrop Advisors LLC Acquires 60 Shares of Illumina, Inc. (NASDAQ:ILMN)

Douglass Winthrop Advisors LLC boosted its position in Illumina, Inc. (NASDAQ:ILMN) by 4.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,568 shares of the life sciences company’s stock after acquiring an additional 60 shares during the period. Douglass Winthrop Advisors LLC’s holdings in Illumina were worth $636,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Evermay Wealth Management LLC bought a new stake in Illumina during the 2nd quarter valued at about $26,000. Activest Wealth Management purchased a new position in shares of Illumina in the second quarter worth $35,000. Lumature Wealth Partners LLC lifted its holdings in shares of Illumina by 241.9% in the third quarter. Lumature Wealth Partners LLC now owns 106 shares of the life sciences company’s stock worth $43,000 after buying an additional 75 shares in the last quarter. Allworth Financial LP raised its stake in Illumina by 1,180.0% during the third quarter. Allworth Financial LP now owns 128 shares of the life sciences company’s stock valued at $52,000 after purchasing an additional 118 shares in the last quarter. Finally, FinTrust Capital Advisors LLC increased its position in Illumina by 953.8% during the second quarter. FinTrust Capital Advisors LLC now owns 137 shares of the life sciences company’s stock valued at $65,000 after acquiring an additional 124 shares during the last quarter. 84.89% of the stock is owned by hedge funds and other institutional investors.

In other Illumina news, SVP Alexander Aravanis sold 2,926 shares of the business’s stock in a transaction that occurred on Tuesday, October 19th. The stock was sold at an average price of $411.82, for a total transaction of $1,204,985.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Susan H. Tousi sold 100 shares of the business’s stock in a transaction that occurred on Thursday, October 28th. The stock was sold at an average price of $414.35, for a total value of $41,435.00. The disclosure for this sale can be found here. Insiders have sold 12,189 shares of company stock valued at $5,024,576 over the last 90 days. Company insiders own 0.23% of the company’s stock.

ILMN traded up $0.01 during trading on Friday, reaching $399.52. 4,467 shares of the stock traded hands, compared to its average volume of 1,085,607. The stock has a market cap of $62.44 billion, a price-to-earnings ratio of 65.60, a price-to-earnings-growth ratio of 3.22 and a beta of 0.90. Illumina, Inc. has a fifty-two week low of $341.03 and a fifty-two week high of $555.77. The company has a debt-to-equity ratio of 0.16, a current ratio of 2.68 and a quick ratio of 2.24. The stock’s 50-day simple moving average is $378.61 and its two-hundred day simple moving average is $429.01.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, November 4th. The life sciences company reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.24 by $0.21. Illumina had a return on equity of 15.03% and a net margin of 21.17%. The business had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter in the previous year, the firm earned $1.02 EPS. The firm’s revenue was up 39.3% compared to the same quarter last year. Research analysts anticipate that Illumina, Inc. will post 5.66 earnings per share for the current fiscal year.

Several equities analysts recently commented on ILMN shares. Citigroup decreased their price objective on shares of Illumina from $450.00 to $400.00 and set a “neutral” rating for the company in a research report on Thursday, January 6th. Zacks Investment Research upgraded Illumina from a “strong sell” rating to a “hold” rating and set a $399.00 price objective on the stock in a report on Tuesday, January 4th. Bank of America upgraded Illumina from an “underperform” rating to a “neutral” rating and set a $390.00 price objective on the stock in a report on Friday, January 7th. Robert W. Baird cut their price objective on Illumina from $493.00 to $437.00 and set a “neutral” rating for the company in a research report on Monday, November 8th. Finally, Barclays raised Illumina from an “underweight” rating to an “equal weight” rating and dropped their target price for the company from $432.72 to $412.00 in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $443.69.

Illumina Company Profile

Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions.

See Also: What does an equal weight rating mean?

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.